You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - other biologic treatment
SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Daniluk S, Skrumsager B, Leszczynski P
SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial
Annals of the Rheumatic Diseases 2014;73:684-685.